iTeos Therapeutics (NASDAQ:ITOS) Stock Rating Lowered by JPMorgan Chase & Co.

iTeos Therapeutics (NASDAQ:ITOS) was downgraded by equities researchers at JPMorgan Chase & Co. from an “overweight” rating to a “neutral” rating in a research note issued to investors on Tuesday, Marketbeat reports. They currently have a $8.00 price target on the stock, down from their prior price target of $15.00. JPMorgan Chase & Co.‘s target price suggests a potential upside of 5.26% from the company’s previous close.

Other equities research analysts have also recently issued research reports about the stock. HC Wainwright reiterated a “buy” rating and set a $46.00 price objective on shares of iTeos Therapeutics in a research report on Thursday, March 6th. Wells Fargo & Company reduced their price objective on shares of iTeos Therapeutics from $17.00 to $16.00 and set an “overweight” rating on the stock in a research report on Tuesday, April 29th. Finally, Wedbush restated an “outperform” rating and issued a $25.00 price target on shares of iTeos Therapeutics in a research report on Wednesday, March 5th. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $17.86.

iTeos Therapeutics Price Performance

iTeos Therapeutics stock opened at $7.60 on Tuesday. The stock has a market cap of $290.88 million, a P/E ratio of -2.41 and a beta of 1.39. iTeos Therapeutics has a 1 year low of $4.80 and a 1 year high of $18.70. The firm’s 50 day moving average price is $6.57 and its 200-day moving average price is $7.43.

iTeos Therapeutics (NASDAQ:ITOS) last released its quarterly earnings data on Monday, April 28th. The company reported ($0.80) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.94) by $0.14. As a group, equities analysts expect that iTeos Therapeutics will post -3.49 EPS for the current year.

Institutional Investors Weigh In On iTeos Therapeutics

Large investors have recently bought and sold shares of the business. Point72 Asia Singapore Pte. Ltd. bought a new stake in iTeos Therapeutics in the fourth quarter worth $42,000. CWM LLC boosted its stake in iTeos Therapeutics by 428.7% during the first quarter. CWM LLC now owns 8,554 shares of the company’s stock worth $51,000 after buying an additional 6,936 shares during the period. Virtus ETF Advisers LLC boosted its stake in iTeos Therapeutics by 58.2% during the fourth quarter. Virtus ETF Advisers LLC now owns 8,948 shares of the company’s stock worth $69,000 after buying an additional 3,293 shares during the period. Forefront Analytics LLC purchased a new position in iTeos Therapeutics during the fourth quarter worth $85,000. Finally, Graham Capital Management L.P. purchased a new position in iTeos Therapeutics during the fourth quarter worth $85,000. Institutional investors own 97.16% of the company’s stock.

iTeos Therapeutics Company Profile

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.